Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion.
We successfully treated a 46-year-old narcoleptic woman suffering from atypical depression with bupropion hydrochloride. Diagnostic evaluation revealed a Beck Depression Inventory (BDI) score of 24, a short nocturnal REM-sleep latency, subjective and objective sleepiness (mean sleep latency (MSL) = 1.8 minutes), and three sleep onset REM-sleep periods during the five nap multiple sleep latency test. Bupropion (100 mg t.i.d.) normalized her mood (BDI = 6), sleepiness (MSL = 9.1 minutes), and REM-sleep propensity. Upon discontinuation of bupropion, these parameters reverted to pretreatment levels. This "activating" antidepressant's reversal of the sleepiness and REM-sleep propensity in narcolepsy may be due to blockade of dopamine or norepinephrine reuptake. Clinicians need to be alert to the fact that depression can mask the diagnosis of narcolepsy. Bupropion warrants further investigation as a treatment for narcolepsy in an open-label, double-blind, placebo-controlled paradigm.
Rye
D B
DB
Department of Neurology, Emory University School of Medicine, Emory Sleep Disorders Center, Wesley Woods Hospital, Atlanta, Georgia, USA.
Dihenia
B
B
Bliwise
D L
DL
D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006801:Humans; D008875:Middle Aged; D009290:Narcolepsy / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D012893:Sleep Wake Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D012895:Sleep, REM / Q000187:drug effects*
D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion; D004298:Dopamine